Nevro announced that the results of the SENZA-RCT study were published online in Anesthesiology, the official journal of the American Society of Anesthesiologists.
Here are five insights:
1. The study compared the safety and effectiveness of HF10 therapy using the SENZA SCS system with traditional spinal cord stimulator therapy.
2. The study enrolled 241 chronic pain patients across 11 U.S. clinical trial sites.
3. Of the 241 patients, 171 received SCS implants at 10 sites.
4. The SENZA system was found to be safe and also had a substantial positive impact on leg and back pain sufferers.
5. The SENZA system is the only SCS system that delivers Nevro's proprietary HF10 therapy.